Do you routinely consider empiric single or dual antifungal therapy in critically ill patients for whom there is high clinical suspicion for acute pulmonary invasive fungal infection?

The patient has prolonged profound neutropenia from methotrexate use in the setting of rheumatoid arthritis, now with severe ARDS of unclear etiology on VV-ECMO and concern for ILD and a plan to start MMF. Beta d glucan is positive with candida growing from BAL culture, otherwise all non invasive fungal markers are negative.